In Utero Exposure to Bioactive Food Components and Mammary Cancer Risk (R21)

archived

Purpose. This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI), the National Institute of Environmental Health Sciences (NIEHS), and the Office of Dietary Supplements (ODS), encourages innovative preclinical research applications that will enhance the understanding of the relationship between exposure(s) to bioactive food components and/or environmental chemicals in utero, hormonal and growth-factor response, gene expression or epigenetic changes, and subsequent mammary cancer risk in preclinical models. Although much evidence suggests that dietary components are linked to cancer prevention, the specific nutrients, sites of action, and role of exposure in utero remain elusive. Similarly, there are data suggesting a role for environmental agents such as mycotoxins, heterocyclic amines, and environmental chemicals with endocrine activity in the etiology of mammary cancer but the doses, windows of susceptibility, and mechanisms are unclear. This FOA encourages applications that apply new high-throughput genomic, epigenomic, proteomic, and metabolomic technologies to determine how dietary exposures in utero influence adult breast cancer susceptibility. The resulting information will help define effective maternal dietary intervention strategies for breast cancer prevention in her offspring. Mechanism of Support. This FOA utilizes the NIH Exploratory/Developmental Grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope, PA-08-140, that solicits applications under the NIH Research Project Grant (R01) mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. Budget and Project Period. The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. The R21 is not renewable. Application Research Plan Component Length: The R21 application Research Plan component of the PHS398 (Items 2-5) may not exceed 15 pages, including tables, graphs, figures, diagrams, and charts. For information on NIH Exploratory/Developmental Research Grant Award (R21). http://grants.nih.gov/grants/funding/funding_program.htm Eligible Institutions/Organizations. Institutions/organizations listed in Section III, 1.A. are eligible to apply. Eligible Project Directors/Principal Investigators (PDs/PIs). Include Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Number of PDs/PIs. More than one PD/PI (i.e., multiple PDs/PIs), may be designated on the application. Number of Applications. Applicants may submit more than one application, provided that each application is scientifically distinct Resubmissions. Applicants may submit a resubmission application, but such application must include an Introduction addressing the previous peer review critique (Summary Statement). Renewals. Exploratory/developmental grant support is for new projects only; competing renewal (formerly competing continuation) applications will not be accepted.

High